Showing results (1-10 of 186) with videos related to
Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2013
What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?Nadine TungGynecologic Oncology|April 30, 2017
Managing hereditary breast cancer risk in women with and without ovarian cancerMary Linton Peters, Judy E Garber, Nadine TungMolecular Cancer Research : MCR|March 11, 2010
Wild-type BRCA1, but not mutated BRCA1, regulates the expression of the nuclear form of beta-cateninHuchun Li, Masayuki Sekine, Nadine Tung, et al.Journal of Oncology Practice|September 12, 2019
When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?Kim DeLeonardis, Lauren Hogan, Stephen A Cannistra, et al.British Journal of Cancer|August 30, 2024
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testingBanu Arun, Fergus J Couch, Jean Abraham, et al.Journal of the National Cancer Institute|August 12, 2025
Q and a on PARP inhibitor use in somatic BRCA-mutated breast cancersNadine Tung, Robert L Hollis, Giuseppe Viale, et al.The Breast Journal|February 1, 2017
Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer PatientsKimberly DeLeonardis, Kristin Sedgwick, Olga Voznesensky, et al.Hereditary Cancer in Clinical Practice|June 11, 2020
Adherence to National Comprehensive Cancer Network Guidelines for <i>BRCA</i> testing among high risk breast Cancer patients: a retrospective chart review studyPriyanka Bobbili, Temitope Olufade, Maral DerSarkissian, et al.Gynecologic Oncology|June 12, 2003
Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian originAnna Berkenblit, Nadine Tung, Young Kim, et al.Pageof 19